Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44507 | 1.00 | SLC6A2 (0.63) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| SCHEMBL896162 | 1.00 | SLC6A2 (0.63) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL25262545 | 0.98 | TAAR1 (0.61) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| Hydrochloric Acid SCHEMBL11481635 | 0.98 | TAAR1 (0.61) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| 1,2-Dichloroethane SCHEMBL27685856 | 0.92 | TAAR1 (0.55) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| SCHEMBL5935521 | 0.83 | TRPA1 (0.58) | SLC6A2TAAR1ESR1KDM4EADRA2A | |
| Hydrochloric Acid SCHEMBL4745937 | 0.83 | TAAR1 (0.54) | SLC6A2TAAR1KDM4EADRA2AHTR1A | |
| Hydrochloric Acid SCHEMBL4748365 | 0.82 | KDM4E (0.57) | SLC6A2TAAR1ESR1KDM4EADRA2A | |
| SCHEMBL104626 | 0.82 | ESR1 (0.59) | SLC6A2TAAR1ESR1ESR2KDM4E | |
| SCHEMBL13698055 | 0.80 | ESR1 (0.56) | SLC6A2TAAR1ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160177354-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | SAFC, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-2462115-B1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS INC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | ROYALTY SECURITY, LLC | 2014-12-18 | — | — | US | disclosed |
| US-8703448-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| CN-102574791-A | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS INC | 2012-07-11 | — | — | CN | disclosed |
| EP-2462115-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | Infinity Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| WO-2011017551-A1 | ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| EP-0987332-B1 | DNA encoding a polypeptide having stereoselective transaminase activity, and transformants comprising said DNA | KANEKA CORP (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-6344351-B2 | USING (R)-FORM-SPECIFIC TRANSAMINASE WITH KETONE AMINO ACCEPTOR AND AMINO DONOR; ANTIDIABETES AND ANTIOBESITY AGENTS | KANEKA CORPORATION (JP) | 2002-02-05 | — | — | US | disclosed |
| US-20010031487-A1 | Process for producing optically active amino compounds | KANEKA CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6221638-B1 | BY STEREOSELECTIVELY CARRYING OUT AMINO GROUP TRANSFER BY ACTION OF AN (R)-FORM-SPECIFIC TRANSAMINASE IN THE CO-PRESENCE OF A KETONE (AMINO ACCEPTOR) AND AMINO COMPOUND (AMINO DONOR); YIELDS AMINO COMPOUNDS HAIVNG ARYL GROUP AT THE 1-POSITION | KANEKA CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-0987332-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | Kaneka Corporation (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0857790-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AMINO COMPOUNDS | KANEKA CORPORATION (JP) | 1998-08-12 | — | — | EP | disclosed |
| EP-0254856-B1 | PYRIDINETHANOL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-04 | — | — | EP | disclosed |
| US-4988714-A | Drugs for treatment of obesity and diabetics, increases protein breakdown, for fattening animals | HOFFMANN-LA ROCHE INC. (US) | 1991-01-29 | — | — | US | disclosed |
| US-4800206-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-01-24 | — | — | US | disclosed |
| EP-0254856-A2 | Pyridinethanol amine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-02-03 | — | — | EP | disclosed |
| EP-0007205-A1 | Optically active phenethanolamines, their formulations, use and preparation | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083607-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | SLC6A2 3119/4885TAAR1 2537/4885ESR1 4827/4885 |
| US-20140371456-A1 | Enzymatic Transamination of Cyclopamine Analogs | TKT, TALDO1, BCHE | SLC6A2 3119/4885TAAR1 2537/4885ESR1 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.